首页 > 用药指导 > 文章详情

以色列梯瓦制药阿那格雷

发布时间:2023-09-20 16:03:02 阅读:232 来源:问药网
分享至

分享到微信朋友圈

×

打开微信,点击底部的“发现”,

使用“扫一扫”即可将网页分享至朋友圈。

阿那格雷

阿那格雷 生产厂家:美国Array BioPharma Inc 功能主治:治疗血小板增多症,降低血栓形成风险,改善患者生存 用法用量:用法用量  1.成人口服给药起始剂量为一次0.5mg,一日4次或一次1mg,一日2次。  1周后可进行剂量调整,但一周中日剂量最多增加0.5mg。  最大剂量不超过一日10mg,单剂量不超过一次2.5mg。  .肝功能不全时剂量应减量给药。  2.儿童口服给药用于6岁以上儿童,起始剂量为0.5mg,顿服。  1周后可进行剂量调整,但一周中日剂量最多增加0.5mg。  最大剂量不超过一日10mg,单剂量不超过一次2.5mg。
查看详情
  First developed in the late 1980s, Anagrelide inhibits the production of platelets in the bone marrow, thus reducing their numbers in the bloodstream. It works by interfering with the enzyme phosphodiesterase III, which is involved in platelet production. By blocking this enzyme, Anagrelide helps to regulate platelet counts and reduce the risk of heart attack, stroke, and other thrombotic events associated with increased platelet levels.
  Anagrelide has significantly revolutionized the treatment of essential thrombocythemia. Prior to its introduction, patients were primarily prescribed aspirin or other agents to prevent blood clotting. However, these medications did not effectively reduce platelet counts in most cases, leaving patients at a higher risk of developing complications. Anagrelide, on the other hand, has demonstrated impressive efficacy in managing elevated platelet counts, thus providing a better quality of life for patients.
阿那格雷  Studies have shown that Anagrelide effectively reduces platelet counts in the majority of patients, typically within a few weeks to months of starting treatment. Additionally, the drug is associated with relatively few side effects which are generally mild and reversible. Common side effects include headaches, fluid retention, and palpitations. However, these side effects are usually well-tolerated, and most patients continue with the medication without significant issues.
  One unique aspect of Anagrelide is that it not only reduces platelet counts but also improves other blood parameters. Studies have shown that it may decrease the size and volume of abnormally large platelets seen in essential thrombocythemia, which further reduces the risk of thrombotic events. This multifaceted action makes Anagrelide an ideal choice for patients with ET.
  Israel-based pharmaceutical company Teva Pharmaceuticals is one of the leading players in the manufacturing and distribution of Anagrelide worldwide. Teva Pharmaceuticals is renowned for its commitment to producing high-quality medications, and Anagrelide is no exception. Leveraging their expertise, the company has ensured that Anagrelide is manufactured in compliance with international pharmaceutical standards, providing patients with a reliable and consistent supply of the medication.
  In conclusion, Anagrelide has transformed the management of essential thrombocythemia, effectively reducing platelet counts and improving blood parameters. Its ability to lower the risk of thrombotic complications has significantly improved the prognosis for patients with this condition. Moreover, the relatively mild side effect profile, along with its mode of action, make it a reliable and preferred treatment option. As a medication produced by Teva Pharmaceuticals, Anagrelide has provided patients worldwide with an effective and consistent approach to managing essential thrombocythemia.